Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25547910 | 0.98 | MAPK1 (0.64) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL22837677 | 0.98 | MAPK1 (0.64) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL22526376 | 0.98 | MAPK1 (0.64) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL10308718 | 0.94 | KDM4E (0.56) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL24029441 | 0.88 | KDM4E (0.52) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL10085297 | 0.85 | KDM4E (0.48) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL22861692 | 0.83 | KMT2A (0.47) | KDM4EMAPK1HIF1AADRA1AEPHX1 | |
| SCHEMBL25170111 | 0.83 | ADRA1A (0.44) | KDM4EMAPK1HIF1AADRA1AEPHX1 | |
| SCHEMBL19170617 | 0.82 | ADRA1A (0.44) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL25974070 | 0.82 | ADRA1A (0.44) | KDM4EMAPK1HIF1AADRA1APAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2020264490-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-9321781-B2 | Topoisomerase inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-04-26 | — | — | US | disclosed |
| US-20120237531-A1 | TOPOISOMERASE INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885MAPK1 2017/4885HIF1A 3588/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885MAPK1 2017/4885HIF1A 3588/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | KDM4E 624/4885MAPK1 2163/4885HIF1A 2282/4885 |
| US-20120237531-A1 | TOPOISOMERASE INHIBITORS | TOP1, TOP2A, TOP2B | KDM4E 1279/4885MAPK1 3769/4885HIF1A 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.